1607831-20-8

Basic information

• Product Name: [8-(4-methoxybenzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl]thiourea
• Synonyms: [8-(4-methoxybenzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl]thiourea
• CAS NO: 1607831-20-8
• Molecular Weight: 362.436
• Mol File: 1607831-20-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [8-(4-methoxybenzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl]thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: [8-(4-methoxybenzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl]thiourea(1607831-20-8)
• EPA Substance Registry System: [8-(4-methoxybenzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrazolo[1,5-a][1,3,5]triazin-7-yl]thiourea(1607831-20-8)

Safety Data

• Hazardous Substances Data: 1607831-20-8(Hazardous Substances Data)

Upstream product

• 163590-19-0 3,5-diamino-4-(4-methoxybenzyl)-1H-pyrazole 
• 5553-92-4 2-(4-methoxybenzyl)malononitrile 
• 123-11-5 4-methoxy-benzaldehyde 
• 1607831-48-0 C₁₉H₂₄N₆O₅S₂ 

Relevant articles and documents

Discovery of mixed type thymidine phosphorylase inhibitors endowed with antiangiogenic properties: Synthesis, pharmacological evaluation and molecular docking study of 2-thioxo-pyrazolo[1,5-a][1,3,5]triazin-4-ones. Part II

In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5] triazin-4-ones were designed, synthesized and evaluated for their TP inhibitory potential. All the synthesized analogues conferred a varying degree of TP inhibitory activity, comparable or better than positive control, 7-deazaxanthine (7-DX, 2) (IC50 value = 42.63 μM). A systematic approach to the lead optimization identified compounds 3c and 4a as the most promising TP inhibitors, exhibiting mixed mode of enzyme inhibition. Moreover, selected compounds demonstrated the ability to attenuate the expression of the angiogenic markers (viz. MMP-9 and VEGF) in MDA-MB-231 cells at sublethal concentrations. In addition, molecular docking studies revealed the plausible binding orientation of these inhibitors towards TP, which was in accordance with the experimental results. Taken as a whole, these compounds would constitute a new direction for the design of novel TP inhibitors with promising antiangiogenic properties.